Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 164

1.

Adherence to the Western, Prudent, and Mediterranean dietary patterns and chronic lymphocytic leukemia in the MCC-Spain study.

Solans M, Castelló A, Benavente Y, Marcos-Gragera R, Amiano P, Gracia-Lavedan E, Costas L, Robles C, Gonzalez Barca E, de la Banda E, Alonso E, Aymerich M, Campo E, Dierssen-Sotos T, Fernández-Tardón G, Olmedo-Requena R, Gimeno E, Castaño-Vinyals G, Aragonés N, Kogevinas M, de Sanjose S, Pollán M, Casabonne D.

Haematologica. 2018 Jun 28. pii: haematol.2018.192526. doi: 10.3324/haematol.2018.192526. [Epub ahead of print]

2.

The expression of cannabinoid type 1 receptor and 2-arachidonoyl glycerol synthesizing/degrading enzymes is altered in basal ganglia during the active phase of levodopa-induced dyskinesia.

Rojo-Bustamante E, Abellanas MA, Clavero P, Thiolat ML, Li Q, Luquin MR, Bezard E, Aymerich MS.

Neurobiol Dis. 2018 Jun 21;118:64-75. doi: 10.1016/j.nbd.2018.06.019. [Epub ahead of print]

PMID:
29936234
3.

Stereological Estimates of Glutamatergic, GABAergic, and Cholinergic Neurons in the Pedunculopontine and Laterodorsal Tegmental Nuclei in the Rat.

Luquin E, Huerta I, Aymerich MS, Mengual E.

Front Neuroanat. 2018 May 11;12:34. doi: 10.3389/fnana.2018.00034. eCollection 2018.

4.

The reference epigenome and regulatory chromatin landscape of chronic lymphocytic leukemia.

Beekman R, Chapaprieta V, Russiñol N, Vilarrasa-Blasi R, Verdaguer-Dot N, Martens JHA, Duran-Ferrer M, Kulis M, Serra F, Javierre BM, Wingett SW, Clot G, Queirós AC, Castellano G, Blanc J, Gut M, Merkel A, Heath S, Vlasova A, Ullrich S, Palumbo E, Enjuanes A, Martín-García D, Beà S, Pinyol M, Aymerich M, Royo R, Puiggros M, Torrents D, Datta A, Lowy E, Kostadima M, Roller M, Clarke L, Flicek P, Agirre X, Prosper F, Baumann T, Delgado J, López-Guillermo A, Fraser P, Yaspo ML, Guigó R, Siebert R, Martí-Renom MA, Puente XS, López-Otín C, Gut I, Stunnenberg HG, Campo E, Martin-Subero JI.

Nat Med. 2018 Jun;24(6):868-880. doi: 10.1038/s41591-018-0028-4. Epub 2018 May 21.

PMID:
29785028
5.

A new molecular assay and genomic complexity predict outcome in conventional and leukemic non-nodal mantle cell lymphoma.

Clot G, Jares P, Giné E, Navarro A, Royo C, Pinyol M, Martín-Garcia D, Demajo S, Espinet B, Salar A, Ferrer A, Muntañola A, Aymerich M, Rauert-Wunderlich H, Jaffe ES, Connors JM, Gascoyne RD, Delabie J, López-Guillermo A, Ott G, Wright GW, Staudt LM, Rosenwald A, Scott DW, Rimsza LM, Beà S, Campo E.

Blood. 2018 May 16. pii: blood-2018-03-838136. doi: 10.1182/blood-2018-03-838136. [Epub ahead of print]

PMID:
29769262
6.

Expression of the transcribed ultraconserved region 70 and the related long non-coding RNA AC092652.2-202 has prognostic value in Chronic Lymphocytic Leukaemia.

Bomben R, Roisman A, D'Agaro T, Castellano G, Baumann T, Delgado J, López-Guillermo A, Zucchetto A, Dal-Bo M, Bravin V, Slavutsky I, Vlasova A, Guigó R, Martin-Subero JI, Chapaprieta V, Beekman R, Martin-García D, Beà S, Salaverria I, Aymerich M, Campo E, Gattei V, Hernández L.

Br J Haematol. 2018 Apr 24. doi: 10.1111/bjh.15237. [Epub ahead of print] No abstract available.

PMID:
29687884
7.

Impact of Neurodegenerative Diseases on Drug Binding to Brain Tissues: From Animal Models to Human Samples.

Ugarte A, Corbacho D, Aymerich MS, García-Osta A, Cuadrado-Tejedor M, Oyarzabal J.

Neurotherapeutics. 2018 Apr 19. doi: 10.1007/s13311-018-0624-5. [Epub ahead of print]

PMID:
29675823
8.

FDI-Unilever Brush Day & Night partnership: 12 years of improving behaviour for better oral health.

Kell K, Aymerich MA, Horn V.

Int Dent J. 2018 May;68 Suppl 1:3-6. doi: 10.1111/idj.12404. Epub 2018 Mar 24.

PMID:
29573414
9.

Determination of hemodynamic risk for vascular disease in planar artery bifurcations.

Otero-Cacho A, Aymerich M, Flores-Arias MT, Abal M, Álvarez E, Pérez-Muñuzuri V, Muñuzuri AP.

Sci Rep. 2018 Feb 12;8(1):2795. doi: 10.1038/s41598-018-21126-1.

10.

Analysis of criteria for treatment initiation in patients with progressive chronic lymphocytic leukemia.

Mozas P, Rivas-Delgado A, Baumann T, Villamor N, Ortiz-Maldonado V, Aymerich M, Costa D, Navarro A, Giné E, López-Guillermo A, Montserrat E, Delgado J.

Blood Cancer J. 2018 Jan 16;8(1):10. doi: 10.1038/s41408-017-0044-5. No abstract available.

11.

Established and suggested exposures on CLL/SLL etiology: Results from the CLL-MCC-Spain study.

Benavente Y, Casabonne D, Costas L, Robles C, Alonso E, de la Banda E, Gonzalez-Barca E, Marcos-Gragera R, Llorca J, Tardón A, Monleon JJ, Aymerich M, Campo E, Gimeno-Vázquez E, Castaño-Vinyals G, Aragonés N, Pollán M, Kogevinas M, de Sanjosé S.

Cancer Epidemiol. 2018 Feb;52:106-111. doi: 10.1016/j.canep.2017.12.012. Epub 2018 Jan 4.

PMID:
29289901
12.

The mutational landscape of small lymphocytic lymphoma compared to non-early stage chronic lymphocytic leukemia.

Martínez-Trillos A, Pinyol M, Delgado J, Aymerich M, Rozman M, Baumann T, González-Díaz M, Hernández JM, Alcoceba M, Muntañola A, Terol MJ, Navarro B, Giné E, Jares P, Beà S, Navarro A, Colomer D, Nadeu F, Colado E, Payer AR, García-Cerecedo T, Puente XS, López-Otin C, Campo E, López-Guillermo A, Villamor N.

Leuk Lymphoma. 2017 Nov 8:1-9. doi: 10.1080/10428194.2017.1397660. [Epub ahead of print]

PMID:
29115891
13.

Do workers' health surveillance examinations fulfill their occupational preventive objective? Analysis of the medical practice of occupational physicians in Catalonia, Spain.

Rodríguez-Jareño MC, Molinero E, de Montserrat J, Vallès A, Aymerich M.

Int J Occup Med Environ Health. 2017 Oct 6;30(6):823-848. doi: 10.13075/ijomeh.1896.00911. Epub 2017 Sep 11.

14.

Clinical impact of the subclonal architecture and mutational complexity in chronic lymphocytic leukemia.

Nadeu F, Clot G, Delgado J, Martín-García D, Baumann T, Salaverria I, Beà S, Pinyol M, Jares P, Navarro A, Suárez-Cisneros H, Aymerich M, Rozman M, Villamor N, Colomer D, González M, Alcoceba M, Terol MJ, Navarro B, Colado E, Payer ÁR, Puente XS, López-Otín C, López-Guillermo A, Enjuanes A, Campo E.

Leukemia. 2018 Mar;32(3):645-653. doi: 10.1038/leu.2017.291. Epub 2017 Sep 19.

15.

Is there a role for minimal residual disease monitoring in the management of patients with hairy-cell leukaemia?

Ortiz-Maldonado V, Villamor N, Baumann T, Aymerich M, Magnano L, Mozas P, Rivas-Delgado A, Martínez-Trillos A, Giné E, Campo E, López-Guillermo A, Delgado J.

Br J Haematol. 2017 Aug 18. doi: 10.1111/bjh.14900. [Epub ahead of print] No abstract available.

PMID:
28832940
16.

GPR55: A therapeutic target for Parkinson's disease?

Celorrio M, Rojo-Bustamante E, Fernández-Suárez D, Sáez E, Estella-Hermoso de Mendoza A, Müller CE, Ramírez MJ, Oyarzábal J, Franco R, Aymerich MS.

Neuropharmacology. 2017 Oct;125:319-332. doi: 10.1016/j.neuropharm.2017.08.017. Epub 2017 Aug 12.

PMID:
28807673
17.

Study of Different Sol-Gel Coatings to Enhance the Lifetime of PDMS Devices: Evaluation of Their Biocompatibility.

Aymerich M, Gómez-Varela AI, Álvarez E, Flores-Arias MT.

Materials (Basel). 2016 Aug 25;9(9). pii: E728. doi: 10.3390/ma9090728.

18.

Laser Surface Microstructuring of Biocompatible Materials Using a Microlens Array and the Talbot Effect: Evaluation of the Cell Adhesion.

Aymerich M, Nieto D, Álvarez E, Flores-Arias MT.

Materials (Basel). 2017 Feb 22;10(2). pii: E214. doi: 10.3390/ma10020214.

19.

Improved classification of leukemic B-cell lymphoproliferative disorders using a transcriptional and genetic classifier.

Navarro A, Clot G, Martínez-Trillos A, Pinyol M, Jares P, González-Farré B, Martínez D, Trim N, Fernández V, Villamor N, Colomer D, Costa D, Salaverria I, Martín-Garcia D, Erber W, López C, Jayne S, Siebert R, Dyer MJS, Wiestner A, Wilson WH, Aymerich M, López-Guillermo A, Sánchez À, Campo E, Matutes E, Beà S.

Haematologica. 2017 Sep;102(9):e360-e363. doi: 10.3324/haematol.2016.160374. Epub 2017 May 18. No abstract available.

20.

Laser technique for the fabrication of blood vessels-like models for preclinical studies of pathologies under flow conditions.

Aymerich M, Álvarez E, Bao-Varela C, Moscoso I, González-Juanatey JR, Flores-Arias MT.

Biofabrication. 2017 Jun 7;9(2):025033. doi: 10.1088/1758-5090/aa6c3d.

PMID:
28393759
21.

Pharmacologic antagonism of dopamine receptor D3 attenuates neurodegeneration and motor impairment in a mouse model of Parkinson's disease.

Elgueta D, Aymerich MS, Contreras F, Montoya A, Celorrio M, Rojo-Bustamante E, Riquelme E, González H, Vásquez M, Franco R, Pacheco R.

Neuropharmacology. 2017 Feb;113(Pt A):110-123. doi: 10.1016/j.neuropharm.2016.09.028. Epub 2016 Sep 28.

PMID:
27693549
22.

Seeing through the smoke: Human and animal studies of cannabis use and endocannabinoid signalling in corticolimbic networks.

Silveira MM, Arnold JC, Laviolette SR, Hillard CJ, Celorrio M, Aymerich MS, Adams WK.

Neurosci Biobehav Rev. 2017 May;76(Pt B):380-395. doi: 10.1016/j.neubiorev.2016.09.007. Epub 2016 Sep 14. Review.

23.

Night shift work and chronic lymphocytic leukemia in the MCC-Spain case-control study.

Costas L, Benavente Y, Olmedo-Requena R, Casabonne D, Robles C, Gonzalez-Barca EM, de la Banda E, Alonso E, Aymerich M, Tardón A, Marcos-Gragera R, Gimeno-Vázquez E, Gómez-Acebo I, Papantoniou K, Castaño-Vinyals G, Aragonés N, Pollán M, Kogevinas M, de Sanjosé S.

Int J Cancer. 2016 Nov 1;139(9):1994-2000. doi: 10.1002/ijc.30272. Epub 2016 Jul 27.

24.

[Quality and compliance with the regulations of workers'health examinations in relation to their preventive purpose].

Rodríguez-Jareño MC, Molinero E, De Montserrat J, Vallès A, Aymerich M.

Arch Prev Riesgos Labor. 2016 Jul-Sep;19(3):146-65. doi: 10.12961/aprl.2016.19.3.02. Catalan, Spanish.

PMID:
27378501
25.

Fatty acid amide hydrolase inhibition for the symptomatic relief of Parkinson's disease.

Celorrio M, Fernández-Suárez D, Rojo-Bustamante E, Echeverry-Alzate V, Ramírez MJ, Hillard CJ, López-Moreno JA, Maldonado R, Oyarzábal J, Franco R, Aymerich MS.

Brain Behav Immun. 2016 Oct;57:94-105. doi: 10.1016/j.bbi.2016.06.010. Epub 2016 Jun 16.

PMID:
27318096
26.

Genes encoding members of the JAK-STAT pathway or epigenetic regulators are recurrently mutated in T-cell prolymphocytic leukaemia.

López C, Bergmann AK, Paul U, Murga Penas EM, Nagel I, Betts MJ, Johansson P, Ritgen M, Baumann T, Aymerich M, Jayne S, Russell RB, Campo E, Dyer MJ, Dürig J, Siebert R.

Br J Haematol. 2016 Apr;173(2):265-73. doi: 10.1111/bjh.13952. Epub 2016 Feb 25.

PMID:
26917488
27.

The use of clinical practice guidelines in primary care: professional mindlines and control mechanisms.

Gené-Badia J, Gallo P, Caïs J, Sánchez E, Carrion C, Arroyo L, Aymerich M.

Gac Sanit. 2016 Sep-Oct;30(5):345-51. doi: 10.1016/j.gaceta.2016.01.005. Epub 2016 Feb 16.

28.

Clinical impact of MYD88 mutations in chronic lymphocytic leukemia.

Martínez-Trillos A, Navarro A, Aymerich M, Delgado J, López-Guillermo A, Campo E, Villamor N.

Blood. 2016 Mar 24;127(12):1611-3. doi: 10.1182/blood-2015-10-678490. Epub 2016 Feb 4. No abstract available.

29.

Fruit and vegetable intake and vitamin C transporter gene (SLC23A2) polymorphisms in chronic lymphocytic leukaemia.

Casabonne D, Gracia E, Espinosa A, Bustamante M, Benavente Y, Robles C, Costas L, Alonso E, Gonzalez-Barca E, Tardón A, Dierssen-Sotos T, Vázquez EG, Aymerich M, Campo E, Jiménez-Moleón JJ, Marcos-Gragera R, Castaño-Vinyals G, Aragones N, Pollan M, Kogevinas M, Urtiaga C, Amiano P, Moreno V, de Sanjose S.

Eur J Nutr. 2017 Apr;56(3):1123-1133. doi: 10.1007/s00394-016-1162-8. Epub 2016 Feb 2.

PMID:
26838684
30.

Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia.

Nadeu F, Delgado J, Royo C, Baumann T, Stankovic T, Pinyol M, Jares P, Navarro A, Martín-García D, Beà S, Salaverria I, Oldreive C, Aymerich M, Suárez-Cisneros H, Rozman M, Villamor N, Colomer D, López-Guillermo A, González M, Alcoceba M, Terol MJ, Colado E, Puente XS, López-Otín C, Enjuanes A, Campo E.

Blood. 2016 Apr 28;127(17):2122-30. doi: 10.1182/blood-2015-07-659144. Epub 2016 Feb 2.

31.

CD69 expression potentially predicts response to bendamustine and its modulation by ibrutinib or idelalisib enhances cytotoxic effect in chronic lymphocytic leukemia.

Montraveta A, Lee-Vergés E, Roldán J, Jiménez L, Cabezas S, Clot G, Pinyol M, Xargay-Torrent S, Rosich L, Arimany-Nardí C, Aymerich M, Villamor N, López-Guillermo A, Pérez-Galán P, Roué G, Pastor-Anglada M, Campo E, López-Guerra M, Colomer D.

Oncotarget. 2016 Feb 2;7(5):5507-20. doi: 10.18632/oncotarget.6685.

32.

CD49d (ITGA4) expression is a predictor of time to first treatment in patients with chronic lymphocytic leukaemia and mutated IGHV status.

Baumann T, Delgado J, Santacruz R, Martínez-Trillos A, Rozman M, Aymerich M, López C, Costa D, Carrió A, Villamor N, Montserrat E.

Br J Haematol. 2016 Jan;172(1):48-55. doi: 10.1111/bjh.13788. Epub 2015 Nov 12.

PMID:
26559905
33.

Structures for G-Protein-Coupled Receptor Tetramers in Complex with G Proteins.

Cordomí A, Navarro G, Aymerich MS, Franco R.

Trends Biochem Sci. 2015 Oct;40(10):548-551. doi: 10.1016/j.tibs.2015.07.007.

34.

Laser-based surface multistructuring using optical elements and the Talbot effect.

Aymerich M, Nieto D, Flores-Arias MT.

Opt Express. 2015 Sep 21;23(19):24369-82. doi: 10.1364/OE.23.024369.

PMID:
26406642
35.

Detection of chromothripsis-like patterns with a custom array platform for chronic lymphocytic leukemia.

Salaverria I, Martín-Garcia D, López C, Clot G, García-Aragonés M, Navarro A, Delgado J, Baumann T, Pinyol M, Martin-Guerrero I, Carrió A, Costa D, Queirós AC, Jayne S, Aymerich M, Villamor N, Colomer D, González M, López-Guillermo A, Campo E, Dyer MJ, Siebert R, Armengol L, Beà S.

Genes Chromosomes Cancer. 2015 Nov;54(11):668-80. doi: 10.1002/gcc.22277. Epub 2015 Aug 25.

36.

A laser-based technology for fabricating a soda-lime glass based microfluidic device for circulating tumour cell capture.

Nieto D, Couceiro R, Aymerich M, Lopez-Lopez R, Abal M, Flores-Arias MT.

Colloids Surf B Biointerfaces. 2015 Oct 1;134:363-9. doi: 10.1016/j.colsurfb.2015.07.007. Epub 2015 Jul 11.

PMID:
26218523
37.

Non-coding recurrent mutations in chronic lymphocytic leukaemia.

Puente XS, Beà S, Valdés-Mas R, Villamor N, Gutiérrez-Abril J, Martín-Subero JI, Munar M, Rubio-Pérez C, Jares P, Aymerich M, Baumann T, Beekman R, Belver L, Carrio A, Castellano G, Clot G, Colado E, Colomer D, Costa D, Delgado J, Enjuanes A, Estivill X, Ferrando AA, Gelpí JL, González B, González S, González M, Gut M, Hernández-Rivas JM, López-Guerra M, Martín-García D, Navarro A, Nicolás P, Orozco M, Payer ÁR, Pinyol M, Pisano DG, Puente DA, Queirós AC, Quesada V, Romeo-Casabona CM, Royo C, Royo R, Rozman M, Russiñol N, Salaverría I, Stamatopoulos K, Stunnenberg HG, Tamborero D, Terol MJ, Valencia A, López-Bigas N, Torrents D, Gut I, López-Guillermo A, López-Otín C, Campo E.

Nature. 2015 Oct 22;526(7574):519-24. doi: 10.1038/nature14666. Epub 2015 Jul 22.

PMID:
26200345
38.

The splicing modulator sudemycin induces a specific antitumor response and cooperates with ibrutinib in chronic lymphocytic leukemia.

Xargay-Torrent S, López-Guerra M, Rosich L, Montraveta A, Roldán J, Rodríguez V, Villamor N, Aymerich M, Lagisetti C, Webb TR, López-Otín C, Campo E, Colomer D.

Oncotarget. 2015 Sep 8;6(26):22734-49.

39.

Neuroprotective Effect of JZL184 in MPP(+)-Treated SH-SY5Y Cells Through CB2 Receptors.

Aymerich MS, Rojo-Bustamante E, Molina C, Celorrio M, Sánchez-Arias JA, Franco R.

Mol Neurobiol. 2016 May;53(4):2312-9. doi: 10.1007/s12035-015-9213-3. Epub 2015 May 15.

PMID:
25976369
40.

Aberrant Epstein-Barr virus antibody patterns and chronic lymphocytic leukemia in a Spanish multicentric case-control study.

Casabonne D, Benavente Y, Robles C, Costas L, Alonso E, Gonzalez-Barca E, Tardón A, Dierssen-Sotos T, Vázquez EG, Aymerich M, Campo E, Castaño-Vinyals G, Aragones N, Pollan M, Kogevinas M, Juwana H, Middeldorp J, de Sanjose S.

Infect Agent Cancer. 2015 Feb 9;10:5. doi: 10.1186/1750-9378-10-5. eCollection 2015.

41.

Seroreactivity against Merkel cell polyomavirus and other polyomaviruses in chronic lymphocytic leukaemia, the MCC-Spain study.

Robles C, Casabonne D, Benavente Y, Costas L, Gonzalez-Barca E, Aymerich M, Campo E, Tardon A, Jiménez-Moleón JJ, Castaño-Vinyals G, Dierssen-Sotos T, Michel A, Kranz L, Aragonés N, Pollan M, Kogevinas M, Pawlita M, de Sanjose S.

J Gen Virol. 2015 Aug;96(8):2286-92. doi: 10.1099/vir.0.000167. Epub 2015 Apr 28.

PMID:
25920529
42.

How much do workers' health examinations add to health and safety at the workplace? Occupational preventive usefulness of routine health examinations.

Rodríguez-Jareño MC, Molinero E, de Montserrat J, Vallès A, Aymerich M.

Gac Sanit. 2015 Jul-Aug;29(4):266-73. doi: 10.1016/j.gaceta.2014.11.001. Epub 2014 Dec 17.

43.

Dual PI3K/mTOR inhibition is required to effectively impair microenvironment survival signals in mantle cell lymphoma.

Rosich L, Montraveta A, Xargay-Torrent S, López-Guerra M, Roldán J, Aymerich M, Salaverria I, Beà S, Campo E, Pérez-Galán P, Roué G, Colomer D.

Oncotarget. 2014 Aug 30;5(16):6788-800.

44.

A B-cell epigenetic signature defines three biologic subgroups of chronic lymphocytic leukemia with clinical impact.

Queirós AC, Villamor N, Clot G, Martinez-Trillos A, Kulis M, Navarro A, Penas EM, Jayne S, Majid A, Richter J, Bergmann AK, Kolarova J, Royo C, Russiñol N, Castellano G, Pinyol M, Bea S, Salaverria I, López-Guerra M, Colomer D, Aymerich M, Rozman M, Delgado J, Giné E, González-Díaz M, Puente XS, Siebert R, Dyer MJ, López-Otín C, Rozman C, Campo E, López-Guillermo A, Martín-Subero JI.

Leukemia. 2015 Mar;29(3):598-605. doi: 10.1038/leu.2014.252. Epub 2014 Aug 25.

PMID:
25151957
45.

Genomic complexity and IGHV mutational status are key predictors of outcome of chronic lymphocytic leukemia patients with TP53 disruption.

Delgado J, Salaverria I, Baumann T, Martínez-Trillos A, Lee E, Jiménez L, Navarro A, Royo C, Santacruz R, López C, Payer AR, Colado E, González M, Armengol L, Colomer D, Pinyol M, Villamor N, Aymerich M, Carrió A, Costa D, Clot G, Giné E, López-Guillermo A, Campo E, Beà S.

Haematologica. 2014 Nov;99(11):e231-4. doi: 10.3324/haematol.2014.108365. Epub 2014 Jul 4. No abstract available.

46.

Monoacylglycerol lipase inhibitor JZL184 is neuroprotective and alters glial cell phenotype in the chronic MPTP mouse model.

Fernández-Suárez D, Celorrio M, Riezu-Boj JI, Ugarte A, Pacheco R, González H, Oyarzabal J, Hillard CJ, Franco R, Aymerich MS.

Neurobiol Aging. 2014 Nov;35(11):2603-2616. doi: 10.1016/j.neurobiolaging.2014.05.021. Epub 2014 May 28.

PMID:
24973119
47.

Chronic lymphocytic leukemia in the elderly: clinico-biological features, outcomes, and proposal of a prognostic model.

Baumann T, Delgado J, Santacruz R, Martínez-Trillos A, Royo C, Navarro A, Pinyol M, Rozman M, Pereira A, Villamor N, Aymerich M, López C, Carrió A, Montserrat E.

Haematologica. 2014 Oct;99(10):1599-604. doi: 10.3324/haematol.2014.107326. Epub 2014 Jun 27.

48.

Mutations in TLR/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome.

Martínez-Trillos A, Pinyol M, Navarro A, Aymerich M, Jares P, Juan M, Rozman M, Colomer D, Delgado J, Giné E, González-Díaz M, Hernández-Rivas JM, Colado E, Rayón C, Payer AR, Terol MJ, Navarro B, Quesada V, Puente XS, Rozman C, López-Otín C, Campo E, López-Guillermo A, Villamor N.

Blood. 2014 Jun 12;123(24):3790-6. doi: 10.1182/blood-2013-12-543306. Epub 2014 Apr 29.

49.

The γ-secretase inhibitor PF-03084014 combined with fludarabine antagonizes migration, invasion and angiogenesis in NOTCH1-mutated CLL cells.

López-Guerra M, Xargay-Torrent S, Rosich L, Montraveta A, Roldán J, Matas-Céspedes A, Villamor N, Aymerich M, López-Otín C, Pérez-Galán P, Roué G, Campo E, Colomer D.

Leukemia. 2015 Jan;29(1):96-106. doi: 10.1038/leu.2014.143. Epub 2014 Apr 30.

PMID:
24781018
50.

The prognostic impact of minimal residual disease in patients with chronic lymphocytic leukemia requiring first-line therapy.

Santacruz R, Villamor N, Aymerich M, Martínez-Trillos A, López C, Navarro A, Rozman M, Beà S, Royo C, Cazorla M, Colomer D, Giné E, Pinyol M, Puente XS, López-Otín C, Campo E, López-Guillermo A, Delgado J.

Haematologica. 2014 May;99(5):873-80. doi: 10.3324/haematol.2013.099796. Epub 2014 Apr 3.

Supplemental Content

Loading ...
Support Center